Sign in
CompletedNo phase

Evaluation of In-lab Benefit for Speech-in-noise Intelligibility With Device for Adults With Mild to Moderate Hearing Loss

Key facts

Who runs it
Luxottica Group S.p.A.
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
21 people enrolled
Started
23 Jun 2025
Ended
28 Aug 2025
Type of study
Interventional
Treatments tested
  • Evaluation of speech-in-noise intelligibility and listening effort
Record updated
5 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adults aged 18 years and older
  • symmetrical bilateral mild to moderate sensorineural hearing loss
  • native speakers of English

Who cannot take part

  • Children
  • those without hearing loss
  • those without symmetrical bilateral mild to moderate sensorineural hearing loss
  • those who do not wish to wear the test device instead of their own spectacles during the in-lab procedure
  • those who are not native speakers of English
  • those who have pacemakers, other implantable devices, or insulin pumps

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluation of in-lab benefit for speech-in-noise intelligibility with the device for adults with mild to moderate hearing loss.

The group in the trial

  • A prospective in-lab within-subjects design with repeated measuresTreatment being tested

    Test of speech recognition in noise (the Matrix test). Assessment of speech recognition in babble (The Connected Speech Test). Device users' ratings of listening effort in noise with and without the device.

    Treatment: Evaluation of speech-in-noise intelligibility and listening effort

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
In-Lab Evaluation of A Hearing Aid Housed in Ophthalmic Spectacles for Mild to Moderate Hearing Loss
Record updated
5 September 2025